Showing 431-440 of 450 results for "".
- Lineage Cell Therapeutics Reports Regeneration of Retinal Tissue in Patient Treated With OpRegen RPE Cells for Dry AMD With GAhttps://modernod.com/news/lineage-cell-therapeutics-reports-regeneration-of-retinal-tissue-in-patient-treated-with-opregen-rpe-cells-for-dry-amd-with-ga/2477845/Lineage Cell Therapeutics announced that restoration of retinal tissue was observed in a patient enrolled in a phase 1/2a study of its lead product candidate, OpRegen, a retinal pigment epithelium (RPE) cell transplant therapy in development for the treatment of dry age-related macular degenerati
- Lineage Cell Therapeutics Reports New Data With OpRegen for the Treatment of Dry AMD With Geographic Atrophyhttps://modernod.com/news/lineage-cell-therapeutics-reports-new-data-with-opregen-for-the-treatment-of-dry-amd-with-geographic-atrophy/2477713/Lineage Cell Therapeutics announced that updated results from a phase 1/2a study of its lead product candidate OpRegen, a retinal pigment epithelium (RPE) cell transplant therapy currently in development for the treatment of dry age-related macular degeneration (AMD), were published online via th
- Lineage Provides Positive Update on Phase 1/2a Clinical Study of OpRegen for the Treatment of Dry Age-Related Macular Degenerationhttps://modernod.com/news/lineage-provides-positive-update-on-phase-i-iia-clinical-study-of-opregen-for-the-treatment-of-dry-age-related-macular-degeneration/2477278/Lineage Cell Therapeutics a clinical-stage biotechnology company developing novel cellular therapies for unmet medical needs, today provided an update from its ongoing phase 1/2a clinical study of OpRegen, the company’s retinal pigment epithelium (RPE) transplant therapy, for the treatment of dry
- Lineage Provides Update on Patient Enrollment in Phase 1/2a Clinical Study of OpRegen for the Treatment of Dry AMDhttps://modernod.com/news/lineage-provides-update-on-patient-enrollment-in-phase-1-2a-clinical-study-of-opregen-for-the-treatment-of-dry-amd/2477194/Lineage Cell Therapeutics announced additional patient data from its ongoing phase 1/2a clinical study of OpRegen, the company’s retinal pigment epithelium (RPE) transplant therapy, for the treatment of dry age-related macular degeneration (AMD). The first Cohort 4 patient treated using bo
- Lineage Cell Therapeutics Presents Encouraging Data on Vision Restoration Programhttps://modernod.com/news/lineage-cell-therapeutics-presents-encouraging-data-on-vision-restoration-program/2477041/Lineage Cell Therapeutics announced today that Igor Nasonkin, PhD, Principal Investigator and Director of R&D, served as a co-Chair of the Neural Differentiation, Transplantation, and Regeneration Nanosymposium, in addition to presenting data on the company’s Vision Restoration Program at Neu
- Lineage Cell Therapeutics Launches New Corporate Brandhttps://modernod.com/news/lineage-cell-therapeutics-launches-new-corporate-brand/2479549/Lineage Cell Therapeutics, previously BioTime, announced the effective change of its corporate name and formal launch of its new corporate brand. In connection with the launch, the company’s NYSE American ticker symbol has changed to “LCTX” and will be effective at the open of t
- BioTime Announces Name Change to Lineage Cell Therapeuticshttps://modernod.com/news/biotime-announces-name-change-to-lineage-cell-therapeutics/2479562/In a move to reflects the company’s commitment to becoming a leading cell therapy company, BioTime announced it is launching a new corporate brand, including a change of its corporate name to Lineage Cell Therapeutics, effective August 12, 2019. In connection with the launch, the com
- SECO 20/20 Unveils Exclusive Lineup of “Special Sessions”https://modernod.com/news/seco-20-20-unveils-exclusive-lineup-of-special-sessions/2477292/SECO 20/20 has announced the list of 11 speakers who will be featured during the event’s Special Sessions. From March 4-8, 2020, SECO 20/20 will bring together optometric professionals from around the globe to discuss the latest innovations, while discovering cutting-edge lab techniques and infor
- Alcon Showcases Breakthrough Innovations and New Clinical Data at AAO 2025https://modernod.com/news/alcon-showcases-breakthrough-innovations-and-new-clinical-data-at-aao-2025/2484167/Alcon will highlight a lineup of new technologies and clinical data at the 2025 American Academy of Ophthalmology (AAO) annual meeting, October 18–20, in Orlando. At booth #2120, ophthalmologists, surgical staff,
- Alcon Showcases Five Innovations Across Multiple Specialty Areas at ASCRS 2025https://modernod.com/news/alcon-showcases-five-innovations-across-multiple-specialty-areas-at-ascrs-2025/2482744/Alcon announced its lineup of new product offerings at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, April 25-28, in Los Angeles. This year’s event will feature Alcon’s most recent product introductions across specialty areas rangi